EGFR and colorectal carcinoma: Combination chemotherapy, consisting of 5-fluorouracil (5-FU) or oral 5-FU analogues, irinotecan and oxaliplatin, with or without anti-epidermal growth factor receptor (anti-EGFR) and anti-angiogenesis monoclonal antibody, are adopted as the standard first- or second-line therapy for CRC [5–9].